Novel biomarkers, such as Kidney injury molecule 1 (KIM-1), urinary NGAL, a plasma serum cystatin C (CysC), and hepcidin regulatory protein (HJV) have been discovered in succession and brought the potentiality of early diagnosis of postoperative AKI [14–16], but some practical clinical application still suffer from the narrow applicable scope of diseases and lack of a broad international consensus. This evidence concerns the gene LCN2 and acute kidney injury.